Table 2.
Characteristics of patients with nephrotic syndrome and healthy controls
| Case | Age | Sex | sCre | M-Alb/cre (mg/g cre) | HT | Duration of disease prior to biopsy (months) | Hematuria | Previous Treatment |
|---|---|---|---|---|---|---|---|---|
| FGS 1 | 45 | M | 0.61 | 6087 | + | 1 | 2+ | ARB |
| Statin | ||||||||
| FGS 2 | 47 | M | 3.50 | 4338 | + | 12 | 1+ | ARB |
| CCB | ||||||||
| statin | ||||||||
| MC 1 | 24 | M | 0.71 | 3376 | - | 1 | 2+ | - |
| MC 2 | 27 | M | 0.65 | 2868 | - | 1 | 1+ | - |
| Amy1 | 73 | M | 0.83 | 4680 | - | 4 | 1+ | - |
| Amy 2 | 82 | F | 0.65 | 5381 | + | 1 | 2+ | ARB |
| Statin | ||||||||
| Amy 3 | 72 | F | 0.9 | 3600 | - | 48 | 2+ | ARB |
| ConB1 | 44 | M | - | - | - | - | - | - |
| ConB2 | 66 | M | - | - | - | - | - | - |
| ConB3 | 78 | M | - | - | - | - | - | - |
sCre serum creatinine (mg/dL), ARB angiotensin II type 1 receptor blocker, CCB calcium channel blocker, MC minimal change, FGS focal segmental glomerular sclerosis, Amy AL amyloidosis, ConB1-3 three age-matched control, which were not obtained in a series of consecutive patients